Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Company Performance - Merus N.V. reported a quarterly loss of $1.40 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.16, and compared to a loss of $0.59 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $26.49 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 238.55%, and showing a substantial increase from year-ago revenues of $7.89 million [2] - Over the last four quarters, Merus has surpassed consensus EPS estimates only once, but has topped consensus revenue estimates two times [2] Stock Outlook - Merus shares have declined approximately 6.2% since the beginning of the year, while the S&P 500 has seen a decline of 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$1.16 on revenues of $18.92 million, and for the current fiscal year, it is -$4.48 on revenues of $45.11 million [7] - The estimate revisions trend for Merus is mixed, resulting in a Zacks Rank 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Merus belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]